Drugs / Milvexian
Trials 24 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 119 trials | ||||||
| Phase 1 | NCT05706753 | Jan → Jul 2023 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT04965389 | Jul → Aug 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04388501 | Jun → Oct 2021 | — | Janssen Pharmaceutica N.V., Belgium | Completed | No outcome recorded |
| Phase 1 | NCT04844424 | Apr 2021 → May 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04569695 | Mar → Dec 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04543383 | Jul 2020 → Jun 2023 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04448964 | Jun → Nov 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04223349 | Jan → Apr 2020 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04206488 | Jan 2020 → Jun 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT03698513 | Oct 2018 → Feb 2019 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02982707 | Mar → Sep 2018 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03362437 | Nov → Dec 2017 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03341390 | Oct → Nov 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03196206 | Jul 2017 → Mar 2018 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT03224260 | Jun → Nov 2017 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02902679 | Nov 2016 → Jun 2017 | end stage renal failure, impaired renal function disease, thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02959060 | Nov → Dec 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02807909 | Jul → Aug 2016 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02608970 | Dec 2015 → Jul 2017 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03891524 | Jun 2019 → Apr 2021 | osteoarthritis, knee | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03766581 | Jan 2019 → Mar 2022 | transient ischemic attack | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05757869 | Apr 2023 → Oct 2026 expected | atrial fibrillation | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05754957 | Apr 2023 → Feb 2026 | acute coronary syndrome | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT05702034 | Feb 2023 → Nov 2026 expected | ischemic stroke | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03939702 Comparator | May → Jul 2019 | thrombotic disease | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03000673 Comparator | May → Oct 2017 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 28 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Milvexian | “Milvexian (BMS-986177/JNJ-70033093) is a potent, oral small molecule that inhibits the active form of factor XI with high affinity and selectivity.” PMID 36564395 ↗ Dec 202210“Single-Dose Pharmacokinetics of Milvexian in Participants with Normal Renal Function and Participants with Moderate or Severe Renal Impairment.” PMID 35906349 ↗ Jul 2022 “A Study to Assess the Absolute Oral Bioavailability of Milvexian Using a 14C-Microtracer and Oral Solution in Healthy Participants” NCT04965389 ↗ “Milvexian (BMS-986177/JNJ-70033093) is a small-molecule, active-site inhibitor of activated Factor XI (FXIa).” PMID 35262846 ↗ Mar 2022 |
| Known as | BMS-986177 | “Milvexian (BMS-986177/JNJ-70033093) is a small-molecule, active-site inhibitor of activated Factor XI (FXIa).” PMID 35262846 ↗ Mar 202212“A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants” NCT04223349 ↗ |
| Known as | JNJ-70033093 | “Milvexian (BMS-986177/JNJ-70033093) is a potent, oral small molecule that inhibits the active form of factor XI with high affinity and selectivity.” PMID 36564395 ↗ Dec 20226“Milvexian (BMS-986177/JNJ-70033093) is a small-molecule, active-site inhibitor of activated Factor XI (FXIa).” PMID 35262846 ↗ Mar 2022 |
| Action | Inhibit | “inhibits the active form of factor XI with high affinity and selectivity” PMID 36564395 ↗ Dec 20221“Coagulation factor XI inhibitor” CHEMBL4112929 ↗ |
| Modality | Small molecule | “oral small molecule” PMID 36564395 ↗ Dec 2022 |
| Route | Oral | “An oral dose of BMS-986177 administered in End-stage Renal Dysfunction (ESRD) participants” NCT02902679 ↗ |
| Target | F11 | “Coagulation factor XI inhibitor” CHEMBL4112929 ↗ |